ArticleComputational and structural biotechnology journal2026
The Interaction between the Tyrosine Kinase Receptor EphA2 and RNF5: Structural Insights from an
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EphA2 is a tyrosine kinase receptor from the Eph (erythropoietin-producing hepatocellular) family that is involved in several processes associated with regular cellular functions, as well as in different pathological conditions including cancer. EphA2 is up-regulated in many types of tumors, and the process of ligand-triggered receptor endocytosis and the subsequent degradation attract a lot of attention as a means of reducing receptor levels and its pro-oncogenic outcomes. In this context, the intracellular Sam (sterile alpha motif) domain of EphA2 (EphA2-Sam) plays an important role, being the region able to engage protein regulators of receptor endocytosis and stability. Recently, a novel cancer-related interaction involving the E3 ubiquitin ligase RNF5 and EphA2-Sam has been identified. Intriguingly, RNF5 is responsible for lowering receptor stability by targeting it for ubiquitination and consequent degradation. In certain types of breast cancer cells, down-regulation of EphA2 induced by RNF5 overexpression fosters pro-tumorigenic effects while RNF5 silencing and consequent EphA2 amplified regulation induces anticancer outcomes. Immunoprecipitation experiments point out that the membrane-binding domain of RNF5 interacts with EphA2-Sam, but detailed structural information on this protein-protein association is currently missing. To obtain fast insights into structural features governing the molecular recognition between RNF5 and EphA2, we set up an
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.